Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 6/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946467 | 0.99 | IP6K1 (0.48) | IP6K1CNR1SCN9ASCN5ADPP4 | |
| SCHEMBL412178 | 0.79 | KMT2A (0.50) | IP6K1CNR1KMT2AHCAR2 | |
| SCHEMBL15350525 | 0.79 | KMT2A (0.41) | IP6K1CNR1SCN9ASCN5AACACB | |
| SCHEMBL14784457 | 0.78 | CA2 (0.47) | IP6K1CNR1SCN9ASCN5AKMT2A | |
| SCHEMBL20021958 | 0.78 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL411076 | 0.78 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL11463519 | 0.78 | IP6K1 (0.46) | IP6K1CNR1SCN9ASCN5AKMO | |
| SCHEMBL72986 | 0.77 | KMT2A (0.54) | KMT2A | |
| SCHEMBL2701812 | 0.77 | CNR1 (0.72) | IP6K1CNR1CNR2KMT2A | |
| SCHEMBL11471405 | 0.77 | CNR1 (0.47) | IP6K1CNR1SCN9AKMOCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | IP6K1 578/4885CNR1 45/4885SCN9A 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.